{"altmetric_id":16233023,"selected_quotes":["New study: Filgotinib for Treatment of Small Bowel Crohn's Disease (SBCD) #Galapagos $GLPG $GILD"],"citation":{"altmetric_jid":"clinicaltrialsgov","authors":["Gilead Sciences"],"first_seen_on":"2017-02-08T18:55:05+00:00","issns":[],"journal":"ClinicalTrials.gov","last_mentioned_on":1489149106,"links":["https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03046056","https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03046056?term=Glpg&rank=50","https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03046056?term=filgotinib&rank=4"],"nct_id":"NCT03046056","pubdate":"2017-02-06T00:00:00+00:00","publisher":"ClinicalTrials.gov","title":"Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD)","type":"clinical_trial_study_record"},"altmetric_score":{"score":13.2,"score_history":{"1y":13.2,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":13.2},"context_for_score":{"all":{"total_number_of_other_articles":8336644,"mean":7.0294968595789,"rank":649979,"this_scored_higher_than_pct":92,"this_scored_higher_than":7685499,"rank_type":"exact","sample_size":8336644,"percentile":92},"similar_age_3m":{"total_number_of_other_articles":275482,"mean":12.639933548956,"rank":34931,"this_scored_higher_than_pct":87,"this_scored_higher_than":240469,"rank_type":"exact","sample_size":275482,"percentile":87},"this_journal":{"total_number_of_other_articles":24361,"mean":10.484423070608,"rank":2285,"this_scored_higher_than_pct":90,"this_scored_higher_than":22071,"rank_type":"exact","sample_size":24361,"percentile":90},"similar_age_this_journal_3m":{"total_number_of_other_articles":776,"mean":12.328152258065,"rank":52,"this_scored_higher_than_pct":93,"this_scored_higher_than":724,"rank_type":"exact","sample_size":776,"percentile":93}}},"demographics":{"poster_types":{"member_of_the_public":7},"users":{"twitter":{"cohorts":{"Members of the public":7}}},"geo":{"twitter":{"BE":1,"FR":1,"GB":1,"AU":1}}},"counts":{"total":{"posts_count":8},"news":{"unique_users_count":1,"unique_users":["seeking_alpha"],"posts_count":1},"twitter":{"unique_users_count":7,"unique_users":["MauriceOnTW","BioStockAddict","BiotechRadar","UpsilonGlobal","floszcrxl","YoungChris27040","Smosbos"],"posts_count":7}},"posts":{"twitter":[{"url":"http:\/\/twitter.com\/MauriceOnTW\/statuses\/829403143121334272","license":"gnip","citation_ids":[16233023],"posted_on":"2017-02-08T18:54:53+00:00","author":{"name":"Maurice","image":"https:\/\/pbs.twimg.com\/profile_images\/814112497141772289\/2GAVfe0t_normal.jpg","description":"Biotech, rare diseases and a little baseball","id_on_source":"MauriceOnTW","tweeter_id":"296826530","geo":{"lt":null,"ln":null},"followers":679},"tweet_id":"829403143121334272"},{"url":"http:\/\/twitter.com\/BioStockAddict\/statuses\/829431757527191554","license":"gnip","citation_ids":[16233023],"posted_on":"2017-02-08T20:48:35+00:00","author":{"name":"BioStockAddict","image":"https:\/\/pbs.twimg.com\/profile_images\/1361441632\/BioStockAddict_normal.JPG","description":"Biotech investor and trader, stocks and options.","id_on_source":"BioStockAddict","tweeter_id":"204564525","geo":{"lt":50.85045,"ln":4.34878,"country":"BE"},"followers":2827},"tweet_id":"829431757527191554"},{"url":"http:\/\/twitter.com\/BiotechRadar\/statuses\/829432365076320262","license":"gnip","rt":["BioStockAddict"],"citation_ids":[16233023],"posted_on":"2017-02-08T20:51:00+00:00","author":{"name":"Biotech Radar","image":"https:\/\/pbs.twimg.com\/profile_images\/693444152265146369\/T6cOJomc_normal.png","description":"Anticipate the catalysts of EU biotechs (focus on FR\/BE\/NL\/DE listed in Paris\/Bru.\/Ams.).Views=owner's only.RT\/like =\/= endorsement","id_on_source":"BiotechRadar","tweeter_id":"3142088601","geo":{"lt":46,"ln":2,"country":"FR"},"followers":2497},"tweet_id":"829432365076320262"},{"url":"http:\/\/twitter.com\/UpsilonGlobal\/statuses\/829433040459923456","license":"gnip","rt":["BioStockAddict"],"citation_ids":[16233023],"posted_on":"2017-02-08T20:53:41+00:00","author":{"name":"Upsilon Global","url":"http:\/\/www.upsilonglobal.com","image":"https:\/\/pbs.twimg.com\/profile_images\/823580094132355073\/ZBdqCO3E_normal.jpg","description":"Clinical Partner designed to optimise and streamline clinical development programs through our extended global network of specialist therapeutic experts.","id_on_source":"UpsilonGlobal","tweeter_id":"823577588639666177","geo":{"lt":50.82838,"ln":-0.13947,"country":"GB"},"followers":645},"tweet_id":"829433040459923456"},{"url":"http:\/\/twitter.com\/floszcrxl\/statuses\/829460631350767617","license":"gnip","rt":["BioStockAddict"],"citation_ids":[16233023],"posted_on":"2017-02-08T22:43:19+00:00","author":{"name":"flosz","image":"https:\/\/pbs.twimg.com\/profile_images\/731594030962868224\/fPtH-Z9t_normal.jpg","id_on_source":"floszcrxl","tweeter_id":"142384766","geo":{"lt":null,"ln":null},"followers":384},"tweet_id":"829460631350767617"},{"url":"http:\/\/twitter.com\/YoungChris27040\/statuses\/829538763004997634","license":"gnip","rt":["MauriceOnTW"],"citation_ids":[16233023],"posted_on":"2017-02-09T03:53:47+00:00","author":{"name":"Chris Young","image":"https:\/\/pbs.twimg.com\/profile_images\/832595198987296769\/VjFKip8q_normal.jpg","description":"Advocate #equality #disabilities #health LT #investor \ud83d\udd0eP-value mrkt intel\" #Biotech paradigm-shift research, pre-eminently humane. retweets not endorsements.","id_on_source":"YoungChris27040","tweeter_id":"1415149603","geo":{"lt":-37.83333,"ln":144.96667,"country":"AU"},"followers":1344},"tweet_id":"829538763004997634"},{"url":"http:\/\/twitter.com\/Smosbos\/statuses\/830031698888847361","license":"gnip","rt":["BioStockAddict"],"citation_ids":[16233023],"posted_on":"2017-02-10T12:32:32+00:00","author":{"name":"Vanden Bos smos","image":"https:\/\/pbs.twimg.com\/profile_images\/806959825909387264\/5vaDZhjm_normal.jpg","id_on_source":"Smosbos","tweeter_id":"3423646871","geo":{"lt":null,"ln":null},"followers":2},"tweet_id":"830031698888847361"}],"news":[{"title":"Gilead initiates two new mid-stage studies of filgotinib in Crohn's","url":"http:\/\/ct.moreover.com\/?a=29851793776&p=1pl&v=1&x=NuTW_U-UdJ_8jS7zczvsOQ","license":"public","citation_ids":[16233023],"posted_on":"2017-03-10T12:31:46+00:00","summary":"Galapagos NV (NASDAQ: GLPG ) announces that collaboration partners Gilead Sciences (NASDAQ: GILD ) has initiated two new Phase 2 clinical trials assessing JAK1 inhibitor filgotinib: one in small bowel Crohn's disease and the other in fistulizing\u2026","author":{"name":"Seeking Alpha","url":"http:\/\/seekingalpha.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/665\/normal\/Screen_Shot_2016-01-26_at_13.35.16.png?1453815336"}}]}}